Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration

Fig. 6

Neutralisation of systemic classical complement using ANX-M1 anti-C1q antibody during the time course of photo-oxidative damage (PD) and assessment of the retina at day 12 (a). b Complement activity in the serum was inhibited (> 50% less) in mice treated with ANX-M1 anti-C1q antibody compared to IgG control as examined in the hemolytic assay using sheep red blood cells (P < 0.05). c-e There was no difference in the number of TUNEL+ cells (c), ONL thickness (d) and IBA1+ microglia/macrophages (e) observed between the ANX-M1 anti-C1q antibody cohort and IgG control cohort (P > 0.05). f-h Inhibition of systemic classical complement did not change retinal function, as evident in no significant difference in a-wave (f), b-wave (g) response characteristics and mean amplitudes at highest flash intensities between the two cohorts (h) (P > 0.05). i No significant change in cone response was detected between the two cohorts (P > 0.05). Statistical analyses were determined by an unpaired student t-test or two-way ANOVA followed by post-hoc multiple comparison (*denotes P < 0.05; NS denotes no significance)

Back to article page